Researchers looked at patient-reported outcomes with partial breast vs whole breast irradiation in patients with breast cancer who were not receiving chemotherapy.
An analysis of the phase III SOLO1 trial examined safety signals with olaparib maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation.
Researchers analyzed recurrence and survival outcomes for clear cell ovarian carcinoma in the JGOG3017/GCIG trial.
A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer.
Researchers tested maintenance therapy with rucaparib in a phase III trial of patients with recurrent epithelial ovarian cancer who experienced response to platinum-based chemotherapy.
Researchers tested the administration of bone-targeted agents once every 12 weeks vs once every 4 weeks for a year in patients with metastatic castration-resistant prostate cancer.
The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer.
Researchers tested treatment with bone-protecting agents in men with metastatic castration-resistant prostate cancer treated with enzalutamide or radium-223.
A computer modeling analysis studied the use of NGS and its costs in patients with metastatic non–small-cell lung cancer.
A new study identified several T-cell antigens that are shared between tumor tissue and skin in a cohort of patients with non–small-cell lung cancer who were treated with anti–PD-1 therapy.